Table 1 ACR response rates and NNT at Week 24 among the overall population
Treatment | ACR20 | ACR50 | ACR70 | |||
|---|---|---|---|---|---|---|
Response rate (95% CrI) | NNT (95% CrI) | Response rate (95% CrI) | NNT (95% CrI) | Response rate (95% CrI) | NNT (95% CrI) | |
Placebo | 17.0% (15.4%, 18.7%) | – | 7.0% (5.9%, 8.2%) | – | 2.5% (1.9%, 3.3%) | – |
Adalimumab | 61.2% (47.8%, 73.6%) | 2.3 (1.8, 3.2) | 42.8% (27.0%, 62.5%) | 2.8 (1.8, 4.9) | 40.8% (15.9%, 82.2%) | 2.6 (1.3, 7.4) |
Apremilast | 33.4% (27.1%, 40.4%) | 6.1 (4.4, 9.5) | 15.5% (10.9%, 21.8%) | 11.8 (7.0, 23.5) | 5.0% (2.7%, 9.1%) | 40.3 (15.8, 222.7) |
Certolizumab pegol | 50.2% (38.6%, 62.3%) | 3.0 (2.2, 4.6) | 27.9% (18.0%, 41.8%) | 4.8 (2.9, 8.9) | 16.7% (7.9%, 35.9%) | 7.0 (3.0, 17.8) |
Etanercept | 50.1% (35.2%, 65.5%) | 3.0 (2.1, 5.4) | 46.6% (26.6%, 71.2%) | 2.5 (1.6, 5.1) | 9.1% (2.7%, 32.6%) | 15.2 (3.3, 318.5) |
Golimumab | 61.6% (45.9%, 76.3%) | 2.2 (1.7, 3.4) | 39.8% (22.0%, 64.7%) | 3.1 (1.7, 6.6) | 27.4% (9.2%, 71.8%) | 4.0 (1.4, 14.6) |
Infliximab | 56.2% (39.9%, 72.2%) | 2.6 (1.8, 4.3) | 57.1% (32.7%, 82.5%) | 2.0 (1.3, 3.9) | 34.2% (12.1%, 77.9%) | 3.2 (1.3, 10.3) |
Secukinumab 150Â mg | 51.1% (414%, 61.0%) | 2.9 (2.3, 4.0) | 33.8% (23.5%, 46.8%) | 3.7 (2.5, 6.0) | 27.3% (13.4%, 53.1%) | 4.0 (2.0, 9.0) |
Secukinumab 300Â mg | 55.2% (41.0%, 68.8%) | 2.6 (1.9, 4.1) | 34.0% (20.6%, 51.0%) | 3.7 (2.3, 7.2) | 27.0% (11.3%, 55.7%) | 4.1 (1.9, 11.1) |
Ustekinumab 45Â mg | 35.4% (27.5%, 44.4%) | 5.4 (3.7, 9.2) | 19.9% (13.0%, 29.9%) | 7.7 (4.4, 15.8) | 10.2% (4.8%, 21.9%) | 13.0 (5.2, 39.7) |
Ustekinumab 90Â mg | 39.9% (31.5%, 49.1%) | 4.4 (3.2, 6.7) | 23.5% (15.6%, 34.3%) | 6.1 (3.7, 11.1) | 12.1% (5.9%, 25.2%) | 10.4 (4.4, 27.8) |